Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients

Br J Haematol. 2020 Aug;190(3):461-464. doi: 10.1111/bjh.16680. Epub 2020 May 11.

Affiliations

¹ Service d'hématologie Clinique, CHU de Nantes, France.
² Service d'hématologie Clinique, CHU de Nice, France.
³ service d'hématologie seniors, Hôpital St Louis, APHP, Paris, France.

PMID: 32394477
DOI: 10.1111/bjh.16680

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Abnormal Karyotype
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / administration & dosage
Azacitidine / adverse effects
Azacitidine / therapeutic use*
Bone Marrow Diseases / chemically induced
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Febrile Neutropenia / chemically induced
Female
France / epidemiology
Hospitalization / statistics & numerical data
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality
Male
Multicenter Studies as Topic
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / mortality
Renal Insufficiency, Chronic / epidemiology
Retrospective Studies
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine